9月4日，第十七届中国生物产业大会在光谷开幕。会上发布了中国生物产业大会2025最 具生物制造创新力系列榜单，武汉、上海、北京、杭州、深圳等10个国家生物产业基地获评 最具创新力基地，禾元生物、爱博泰克、友芝友等5家武汉企业，从来自23个国家生物产业 基地的数百个项目中脱颖而出，上榜最具创新企业TOP20。 第十七届中国生物产业大会，2025年9月4日在武汉光谷科技会展中心开幕。 长江日报记者高勇摄 中国生物产业大会是我国生物产业领域层次最高、规模最大、影响最广的大型顶级专业 活动，2007年开始举办，2018年起，以武汉光谷生物城为依托，武汉与广州一道成为中国生 物产业大会永久举办地。 记者在大会现场了解到，今年上半年，光谷生物城新获批14个一类创新药进入临床，数 量创3年同期新高；新获批28个三类医疗器械，已达去年全年总量。目前，光谷生物城在研 一类新药超400个，全省占比达到90%；三类医疗器械获证超307个，全省占比达到70%。 记者在面积多达1万平方米的展区看到，来自光谷生物城的联影医疗、人福医药、禾元 生物、朗来科技等多家头部企业，携带最新成果亮相，其中不乏全球首创。联影医疗展出了 全球首款5.0 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global biotechnology revolution, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy [4][5] Market Performance - The Huazhong Synthetic Biology Index rose by 14.49% to 1709.48 during the week of July 14-18, 2025, outperforming the Shanghai Composite Index by 13.8 percentage points and the ChiNext Index by 11.32 percentage points [5][18] - The overall performance of synthetic biology stocks was strong, with the top six performing companies being all from the pharmaceutical sector, including Kanghong Pharmaceutical (+22%) and Zhejiang Zhenyuan (+19%) [20][23] Company Developments - China National Pharmaceutical invested approximately 6.8 billion yuan to acquire 95.09% of Lixin Pharmaceutical, enhancing its R&D capabilities in oncology [26] - New Fengming invested 100 million yuan in Hefei Lifeng Biotechnology to promote the industrialization of bio-based polyester PEF [26] - Sichuan Huanlong Ecological Technology received approval for a 1.5 billion yuan bamboo fiber project, expected to produce 250,000 tons of bleached bamboo pulp annually [27] - Cargill and HELM AG launched the world's largest bio-based BDO project in Iowa, with an investment of 300 million USD, showcasing the potential of bio-based materials in the chemical industry [29] Industry Financing - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds in 2025. Notable examples include Tuoxin Tiancheng, which raised nearly 40 million USD for T-cell immunotherapy product development [35] - Illimis Therapeutics completed a 58 billion KRW (approximately 42 million USD) B round financing to advance its Alzheimer's disease candidate [35] Research and Development - Fuhong Hanlin announced the completion of the first patient dosing of its innovative HER2 antibody HLX22 in the US, marking a significant milestone in cancer treatment [39] - He Yuan Biotechnology's plant-derived recombinant human serum albumin received approval, representing a breakthrough in the field of plant-based recombinant protein drugs [39]